Immunotherapy + Radiation ± PARP Inhibitor for Prostate Cancer
Trial Summary
The trial does not specify if you need to stop taking your current medications. However, if you are on a 5-alpha reductase inhibitor, it must be stopped at least 60 days before joining the trial.
Pembrolizumab, an immune therapy drug, has shown antitumor activity in certain prostate cancer patients, especially those with specific genetic markers like microsatellite instability. Additionally, PARP inhibitors like Olaparib have shown promise in enhancing the effects of radiation therapy in prostate cancer, suggesting a potential benefit when combined with other treatments.
12345Pembrolizumab, an immunotherapy drug, has been studied in various cancers and is generally considered less toxic than traditional chemotherapy, but it can cause side effects like pneumonitis (lung inflammation) in 1%-5% of patients. In prostate cancer studies, some patients experienced immune-related side effects such as myositis (muscle inflammation) and hypothyroidism (underactive thyroid).
24567This treatment is unique because it combines immunotherapy (Pembrolizumab), radiation, and PARP inhibitors, which may enhance the effectiveness of each component. PARP inhibitors can make cancer cells more sensitive to radiation, potentially allowing for lower doses of radiation, and may also improve the response to immunotherapy by making cancer cells more recognizable to the immune system.
1891011Eligibility Criteria
Men with high-risk localized prostate cancer who meet specific health criteria can join this trial. They must have a certain level of physical fitness, no large pelvic nodes as per CT scans, and agree to use contraception post-treatment. Those with PSA levels over 150ng/ml, extensive prior hormone therapy or radiation to the prostate, other cancers within 2 years, or recent anti-cancer treatments cannot participate.Participant Groups
- Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Renal cell carcinoma
- Cervical cancer
- Endometrial carcinoma
- Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Renal cell carcinoma
- Cervical cancer
- Endometrial carcinoma
- Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1